GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABVC BioPharma Inc (NAS:ABVC) » Definitions » Forward PE Ratio

ABVC BioPharma (ABVC BioPharma) Forward PE Ratio : 0.00 (As of May. 01, 2024)


View and export this data going back to 2004. Start your Free Trial

What is ABVC BioPharma Forward PE Ratio?

ABVC BioPharma's Forward PE Ratio for today is 0.00.

ABVC BioPharma's PE Ratio without NRI for today is 0.00.

ABVC BioPharma's PE Ratio for today is 0.00.


ABVC BioPharma Forward PE Ratio Historical Data

The historical data trend for ABVC BioPharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABVC BioPharma Forward PE Ratio Chart

ABVC BioPharma Annual Data
Trend
Forward PE Ratio

ABVC BioPharma Quarterly Data
Forward PE Ratio

Competitive Comparison of ABVC BioPharma's Forward PE Ratio

For the Biotechnology subindustry, ABVC BioPharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABVC BioPharma's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where ABVC BioPharma's Forward PE Ratio falls into.



ABVC BioPharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


ABVC BioPharma  (NAS:ABVC) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


ABVC BioPharma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of ABVC BioPharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ABVC BioPharma (ABVC BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Executives
Shuling Jiang director, 10 percent owner 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Shih-chen Tseng director 5F., NO. 41-1, LN. 12, SINDONG ST., SONGSHAN DIST, TAIPEI CITY F5 105065
Yoshinobu Odaira director 4823 DUNDAS STREET, THOMDALE, LONDON X0 N6P 1J1
Norimi Sakamoto director 4823 DUNDAS STREET, THRONDALE, LONDON X0 N6P 1J1
Shin-yu Miao director NO. 25-12, AMLIN RD., XITUN DIST., TAICHUNG CITY F5 407676
Tsung Shann Jiang director, officer: CSO and Director 1197 LA PLURISSIMA PL, FREMONT CA 94539
Eugene Jiang director, officer: Chairman of the Board & CBO 1197 LA PLURISSIMA PL, FREMONT CA 94539
Chang-jen Jiang director 1197 LA PLURISSIMA PL, FREMONT CA 94539
Yen-hsin Chou director 13F. NO. 2, MEISHU E. 8TH ST.,, GUSHAN DIST., KAOHSIUNG CITY F5 804413
Chi-hsin Richard King officer: Chief Scientific Officer 11907 GRANT PLACE, SAINT LOUIS MO 63131
Howard Doong officer: Chief Executive Officer 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Chihliang An officer: Chief Financial Officer 32458 JEAN DR, UNION CITY CA 94587
Tsang Ming Jiang director 1197 LA PURISSIMA PL, FREMONT CA 94539
Shulamit Lazar director, 10 percent owner, officer: President,Secretary,Treasurer 8605 SANTA MONICA BOULEVARD, SUITE 41336, LOS ANGELES CA 90069
Kevin Patrick Stolz officer: CFO & Controller 2701 CAMBRIDGE COURT, SUITE 100, AUBURN HILLS MI 48326